NCE-1 Intelligence & Market Opportunity

Duvyzat

Givinostat

Neuromuscular Agents

Oral Suspension

Duvyzat is an oral histone deacetylase inhibitor prescribed for Duchenne muscular dystrophy in patients aged six and older. It slows muscle degeneration, reduces inflammation, and supports muscle strength by modulating gene regulation processes.

Approval Date

21-Mar-24

NCE-1 Date

21-Mar-28

NCE Date

21-Mar-29

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

393

2027

432

2028

484

2029

543

2030

600

2031

597

2032

576

Molecule profile

Details & specifications

Molecule

Givinostat

Innovator

ITALFARMACO SPA

Dosage Form

Oral Suspension

Strength

EQ 8.86 mg base/mL

Therapeutic Category

Neuromuscular Agents

Usage

To treat Duchenne muscular dystrophy in individuals aged 6 years and older

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets